Welcome to our dedicated page for TCDA news (Ticker: TCDA), a resource for investors and traders seeking the latest updates and insights on TCDA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TCDA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TCDA's position in the market.
Tricida, Inc. (Nasdaq: TCDA) announced an update regarding its interactions with the FDA following the End-of-Review Type A Meeting focused on its lead drug candidate, veverimer (TRC101). Veverimer is intended to treat metabolic acidosis in patients with chronic kidney disease (CKD). A conference call and webcast will be held on October 29, 2020, at 8:00 am ET to discuss FDA feedback and future plans. The condition affects an estimated three million CKD patients in the U.S. Further details are available on Tricida’s website.
Tricida, Inc. (Nasdaq: TCDA) is set to present 12 studies at the American Society of Nephrology Kidney Week 2020, highlighting the role of metabolic acidosis in chronic kidney disease (CKD). Key presentations include analyses on the relationship between metabolic acidosis and CKD progression across diverse populations, and the effects of veverimer—a treatment under investigation for metabolic acidosis. The findings aim to enhance understanding of this condition in CKD patients, particularly as there are currently no FDA-approved therapies for chronic metabolic acidosis.